Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study

IntroductionWe designed this phase II trial to evaluate the efficacy and safety of weekly paclitaxel in combination with monthly carboplatin as first-line treatment in elderly patients with advanced non-small cell lung cancer (NSCLC).MethodsMain eligibility criteria were histologically or cytologically proven stage IIIB or IV NSCLC, age ≥70 years, Eastern Cooperative Oncology Group performance status 0-2, and measurable disease. The 4-week–based chemotherapy regimen consisted of carboplatin infusion (area under the concentration-time curve 6 mg/ml-1/min) on day 1 and paclitaxel 90 mg/m2 as a 1-hour infusion on days 1, 8, and 15. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors criteria, and symptoms were evaluated using the Lung Cancer Symptoms Scale. Analyses were performed on an intention-to-treat basis.ResultsFrom February 2002 to August 2003, 51 patients (median age, 74 years) participated in the study. One complete and 21 partial responses were reported by the independent review committee, leading to an intention-to-treat objective response rate of 43% (95% confidence interval, 30–57%). The median progression-free and overall survivals were 7.5 (95% confidence interval, 6.2–9.4) and 13.6 (95% confidence interval, 7.5–17) months, respectively. Longitudinal evaluation of the Lung Cancer Symptoms Scale demonstrated lack of quality of life modification during the treatment period. Neurotoxicity was mild to moderate, with 6% of patients suffering from a grade 3 or 4 neuropathy. Myelosuppression was the main toxicity; 39% of patients experienced grade 3 or 4 neutropenia, 18% experienced grade 3 anemia, and 8% experienced grade 3 or 4 thrombocytopenia. There was no treatment-related death.ConclusionsThe combination of weekly paclitaxel 90 mg/m2 administered on days 1, 8, and 15 plus monthly carboplatin area under the curve 6 on day 1 of a 4-week cycle was feasible and active as a first-line treatment for elderly patients with NSCLC with a good safety profile. These results deserve further analysis to compare the standard care for these patients (monotherapies) with this doublet